Dimethyl Sulfoxide
Apexbio Technology LLC Etodolac 41340-25-4 10mM (in 1mL DMSO)
Etodolac (CAS 41340-25-4) is a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs) It exhibits inhibitory activity against COX-2 with an IC50 of 53 5 nM Etodolac is commonly utilized for research involving inflammatory conditions such as osteoarthritis and rheumatoid arthritis In isolated rabbit articular chondrocytes stimulated with TNF Etodolac prevented apoptotic cell shrinkage and suppressed caspase-3/7 activation Conversely in human malignant rhabdoid tumor cells (FRTK-1) Etodolac induced apoptosis in a dose-dependent manner increasing activities of caspase-3 -8 and -9
Apexbio Technology LLC PF-8380 1144035-53-9 10mM (in 1mL DMSO)
PF-8380 (CAS 1144035-53-9) is a selective inhibitor of autotaxin (ATX) a secreted enzyme with lysophospholipase D activity that converts lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) As increased local LPA production promotes tumor proliferation and invasion targeting ATX reduces LPA synthesis PF-8380 demonstrates potent ATX inhibition (IC50 2 8 nM) significantly lowering LPA in plasma and tissue in rodent models It reduces Akt activation enhances radiosensitivity and diminishes growth and invasion of glioblastoma cells indicating utility in oncology research focused on ATX-LPA signaling pathways
Apexbio Technology LLC Febuxostat 144060-53-7 10mM (in 1mL DMSO)
Febuxostat (CAS 144060-53-7) is a non-purine selective inhibitor of xanthine oxidase (XO) an enzyme involved in purine metabolism responsible for producing uric acid and reactive oxygen species (ROS) It exerts its inhibitory action by noncompetitive binding at the molybdenum-pterin active center of XO effectively inhibiting both its oxidized and reduced forms Compared to allopurinol febuxostat demonstrates notably higher potency with a reported IC50 of 1 8 nM versus 2 9 M Febuxostat is utilized in clinical and preclinical research exploring hyperuricemia gout and associated metabolic disorders
Apexbio Technology LLC Tiplaxtinin(PAI-039)(Synonyms: Tiplaxtinin, PAI-039, Tiplaxtinin (PAI-039), Tiplaxitin, PAI1 inhibitor, PAI-1 antagonist, RWJ-676070), 10mM (in 1mL DMSO), CAS: 393105-53-8.
Tiplaxtinin (PAI-039 CAS 393105-53-8) is an orally bioavailable small molecule inhibitor targeting plasminogen activator inhibitor-1 (PAI-1) a physiological regulator of the plasminogen activation system Elevated PAI-1 levels stabilize thrombi by inhibiting tissue- and urokinase-type plasminogen activators Tiplaxtinin binds selectively to PAI-1 with a Kd of approximately 480 nM and inhibits its activity with an IC50 value around 2 7 M In animal models oral administration of Tiplaxtinin significantly delayed arterial thrombus-induced occlusion supporting its utility as a research tool for studying fibrinolytic pathways and thrombotic disorders
Apexbio Technology LLC Ramelteon(Synonyms: Rozerem, TAK-375, Ramelteon, Melatonin receptor agonist, MT1/MT2 agonist), 10mM (in 1mL DMSO), CAS: 196597-26-9.
Ramelteon (CAS 196597-26-9) is a potent orally active agonist selective for MT1 and MT2 melatonin receptors Structurally characterized by its S-enantiomer and ether functional group ramelteon exhibits high binding affinity toward MT1 and MT2 receptors with reported Ki values of 14 pM and 112 pM respectively whereas affinity for the MT3 receptor is considerably lower (Ki 2650 nM) By activating MT1 and MT2 receptors ramelteon suppresses cAMP production in human cells expressing these receptors with IC50 values of 21 2 pM/L (MT1) and 53 4 pM/L (MT2) Given its receptor selectivity and minimal side-effect profile ramelteon is frequently utilized in research investigating circadian rhythms and sleep disorders